Intracoronary brachytherapy: will it rise from the ashes?
The content discusses the evolution of treatment options for in-stent restenosis, including the use of drug-coated balloons and bioresorbable scaffolds.
Related Articles
Prophylactic stenting of vulnerable plaques: pros and cons
This article discusses the potential and limitations of preventive stenting of vulnerable plaques identified on intravascular imaging to reduce acute coronary syndrome risk, but larger…
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis
Find out more about this article on Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A…
Leaflet modification techniques to mitigate coronary obstruction risk during transcatheter aortic valve implantation
Techniques to mitigate the risk of coronary obstruction during transcatheter aortic valve implantation.
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Find out more about this article on One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Next-day and 48-hour discharge following alternative access for transcatheter aortic valve implantation
Find out more about this article on Next-day and 48-hour discharge following alternative access for transcatheter aortic valve implantation
Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: three-year results of the BIOMAG-I study
Find out more about this article on Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: three-year results of the BIOMAG-I study
Unblinded trials of transcatheter interventions with subjective endpoints: what are the implications?
FDA approval of transcatheter devices for severe tricuspid regurgitation sparks debate on validity of unblinded trials with bias-prone outcomes.
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis
Find out more about this article on Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A…
SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women
Find out more about this article on SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis
Find out more about this article on Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A…